

## Purpose

## **PRI MEASURES**

To provide sample statements that should be included in the radiology report to satisfy specific MIPS Quality Measure specifications.

zotecpartners.com

(It should be noted that this is just a guide and there may be other acceptable ways to document the quality aspects of a measure. Please be sure to contact a member of the Compliance department if you have questions or would like documentation reviewed.)

## **\*\*** Indicates changes and/or additional examples for 2017 Reporting

Quality Measure	Sample Documentation(s)	
Claims, Registry Reporti	Claims, Registry Reporting	
145 - Fluoroscopy **	<ul> <li>Exposure Time and Number of Films</li> <li>Fluoroscopy time was X sec/min. Total # of films = xx</li> <li>A total of xx films were taken during the xx sec/min fluoroscopy time</li> <li>No fluoro utilized; Fluoro time = zero; Fluoro – None <u>OR</u></li> <li>Radiation Exposure Indices</li> <li>**Measure Numerator Update</li> <li>Dosage given in the form of: mGy, DAP Gy-cm<sup>2</sup>, mSv INCLUDING the specific</li> <li>radiation exposure measure: o Skin dose mapping o Peak skin dose (PSD) o</li> <li>Reference air kerma (Ka,r) o Kerma-area product (PKA)</li> <li>Dosage was calculated at 8 mGy according to peak skin dose (PSD) technique.</li> <li>PSD = 10 mGy</li> <li>Skin dose mapping using 6 mGy</li> <li>Reference air kerma = 20 mGy</li> </ul>	
146 - Bi-RADS	<ul> <li>Incomplete, Need additional imaging study (BI-RADS® 0)</li> <li>Negative (BI-RADS® 1)</li> <li>Benign (BI-RADS® 2)</li> <li>Probably Benign (BI-RADS® 3)</li> <li>Suspicious (BI-RADS® 4)</li> <li>Highly suggestive of malignancy (BI-RADS® 5)</li> <li>Known biopsy proven malignancy (BI-RADS® 6)</li> </ul>	
147 - Nuclear Med Bone Scan	<ul> <li>Comparison: MRI L-Spine from 04/10/2016; L-Spine x-ray from 01/21/2016</li> <li>Current bone scan is compared to patient's bone scan from last year</li> <li>Patient has not had previous imaging studies</li> <li>There are no relevant studies available for comparison at this time</li> </ul>	

2017 MIPS Quality Measures

Confidential 1 Documentation Quick Reference Guide Radiology

## DEC PARTNERS

2017 MIPS Quality Measures Documentation Quick Reference Guide Radiology

Measurement in Carotid Studies	required to meet the measure criteria. The validating method for CTA/MRA procedures is considered <u>Direct.</u>
Carotid Studies	The validating method for CTA/MRA procedures is considered <u>Direct.</u>
i	<ul> <li>This is typically NASCET criteria.</li> </ul>
	<ul> <li>Ex: A 30% stenosis at the origin of the right ICA is identified by NAS criteria.</li> </ul>
	<ul> <li>Documentation can also specify a statement such as, "the degree of stenos was calculated in reference to measurements of the distal internal carotid diameter." <u>This means that there must be a statement that any found sten</u> is compared to the distal ICA lumen.</li> </ul>
	<ul> <li>Ex: When compared to the distal ICA lumen normal diameter of 4n the degree of stenosis is 75%.</li> </ul>
	<ul> <li>If there is NO stenosis identified, the validating method used to make that determination must still be documented.</li> </ul>
	• Ex: There is no stenosis found as calculated using NASCET criteria.
	The validating method for the Duplex Ultrasound procedure is considered Indirect.
	<ul> <li>Key terms such a <u>velocities, PSV, EDV</u>, etc. should be referenced throughout the report body.</li> </ul>
225 - Reminder	Patient was entered into a reminder system for annual screening mammogram
System for	notification
Mammogram	Due to advanced breast cancer with bone metastasis, the patient has not been ente
	into a reminder system for annual screening mammogram notification.
	Although not mandatory to state in the report, it is recommended in the case of a
405 – Appropriate	Multiple tiny liver lesions were incidentally noted. Follow-up imaging is recommended.
Follow-Up Imaging for	in one year <u>to monitor for any changes</u> .
Incidental Liver,	Due to patient's known colon cancer, follow-up imaging is recommended for the no
Kidney and Adrenal	– 3 mm hepatic lesion <u>to evaluate for mets</u> .
Lesions	
406 – Appropriate Follow-up Imaging for	Follow-up imaging recommended in one year <u>to assess for interval growth</u> of 7 mm sided thyroid nodule.
Incidental Thyroid	
Nodules	In order to monitor changes of multiple incidental thyroid nodules seen on today's exam, follow-up imaging is recommended.
436 – Radiation	
Consideration for	<ul> <li>CT imaging performed using low-dose technique.</li> </ul>
Adult CT: Utilization of	Auto Exposure Controls were utilized during the CT exam to meet ALARA standards
Dose Lowering	$\square$ radiation dose reduction.
Techniques	Adjustment of mA and/or kV according to patient size was made
	□ SafeCT was utilized to reduce radiation dose to the patient
	Use of iterative reconstruction technique
1	

2017 MIPS Quality Measures

Confidential 2 Documentation Quick Reference Guide Radiology